Grifols To Install The Kiro Oncology Robot At Smilow Cancer Hospital

• First U.S. NCI-designated cancer center installation
• Gravimetric and barcode validation promotes compliance with USP (797) and (800)
• Accommodates a variety of sizes and manufacturers’ source and final containers to mitigate pharmacy disruption
• Simultaneous processing of vial reconstitution and bag filling enhances productivity

LOS ANGELES--(BUSINESS WIRE)--Smilow Cancer Hospital at Yale-New Haven – one of only 45 National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation and a member of the National Comprehensive Cancer Network (NCCN) – will become the first oncology hospital in the U.S. to implement the Kiro Grifols robotic drug compounding system. Smilow will serve as a reference site for Grifols, a global healthcare company with a proven history of high quality and safety.

“We use technology as a tool to help us improve the quality and safety of our pharmaceutical care model.”

In addition to meeting needs for dose accuracy and staff and patient safety, the Kiro Grifols system is expected to enhance productivity at Smilow Cancer Hospital. "The goal of integrating innovative technology such as the Kiro Oncology robot into our systems is to improve patient safety,” said Howard Cohen, RPh, MS, Director of Oncology Pharmacy. “We use technology as a tool to help us improve the quality and safety of our pharmaceutical care model.”

The Grifols implementation team is working with key stakeholders at Smilow to analyze existing workflows and operational demands. Together they are developing workload management plans designed to leverage the strengths of the Kiro Grifols system to optimize efficiency, protect personnel, and advance patient safety.

By applying decades of sterile manufacturing expertise and unparalleled engineering intelligence, Grifols and Kiro have introduced a world-class robotic system, with engineering controls that deliver the precision and flexibility needed to meet the demands of the highly complex chemotherapy compounding process.

The Kiro Oncology system is part of Grifols i.v. TOOLS, a comprehensive suite of offerings designed to help stakeholders in sterile compounding roles meet the demands of USP (797) and (800) compliance. The portfolio includes IV workflow management systems, cleanroom technology, and more, all designed for an integrated approach to achieving safety, accuracy and efficiency.

About Smilow Cancer Hospital at Yale New Haven

Smilow Cancer Hospital at Yale-New Haven is part of the nationally recognized Yale New Haven Hospital, and is affiliated with Yale Cancer Center (YCC), one of only 45 National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Smilow Cancer Hospital is a 14-story, 500,000-square-foot cancer hospital, which includes 168 private inpatient rooms, multidisciplinary outpatient treatment centers, 12 operating rooms, infusion suites, diagnostic imaging services, and specialized women's and children’s services. YCC and Smilow Cancer Hospital are members of the National Comprehensive Cancer Network (NCCN), an alliance of 25 cancer centers in the U.S., whose mission is to improve the quality, effectiveness and efficiency of oncology care so that patients can live better lives. Learn more online at www.ynhh.org/smilow.

About Grifols

Grifols is a global healthcare company with more than 75 years of history improving the health and well-being of people around the world through the development of plasma medicines and hospital and pharmacy products. Grifols is present in more than 100 countries worldwide, with global headquarters in Barcelona, Spain. In 2015, Grifols sales exceeded 3,934 million euros, with a headcount of nearly 14,700 employees. Grifols demonstrates its commitment to advancing healthcare by allocating a significant portion of its annual income to R&D.

Through its Hospital Division, Grifols leverages its extensive in-house expertise in engineering, manufacturing, and process control to deliver consultative planning and a comprehensive suite of products and services, including sophisticated robotic technology for compounding sterile products in hospital pharmacies. Learn more at www.grifols.com.

About Kiro Grifols

In 2014, Grifols strengthened its commitment to research, and the growth of its Hospital Division, by acquiring 50% of Kiro Robotics SL, a technology company specializing in the development of healthcare automation. The resulting company, now called Kiro Grifols SL, is a spin-off of the Mondragon Corporation. Kiro Grifols develops some of the world's most sophisticated hospital pharmacy technology. Learn more at www.kiro-robotics.com.